Skip to main content

Amivantamab

Generic name: amivantamab [ AM-ee-VAN-ti-mab ]
Brand name: Rybrevant
Dosage form: intravenous solution (vmjw 50 mg/mL)
Drug class: Miscellaneous bispecific antibodies

Medically reviewed by Drugs.com on Jul 29, 2024. Written by Cerner Multum.

What is amivantamab?

Amivantamab is used in adults alone or in combination with other cancer medicines to treat non-small cell lung cancer that has spread to other parts of the body (metastatic), cannot be removed with surgery, or after other treatments did not work or stopped working.

Your doctor will make sure you have the correct tumor type to be treated with amivantamab.

Amivantamab may also be used for purposes not listed in this medication guide.

Amivantamab side effects

Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Some side effects may occur during the injection. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.

Amivantamab may cause serious side effects. Call your doctor at once if you have:

Your cancer treatments may be delayed, reduced, or permanently discontinued if you have certain side effects.

Common side effects of amivantamab may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings

Use only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.

Before taking this medicine

Tell your doctor if you have or have ever had lung or breathing problems other than lung cancer.

May harm an unborn baby. You may need to take a pregnancy test before starting this treatment. Use effective birth control while using amivantamab and for at least 3 months after your last dose. Tell your doctor if you become pregnant or think you may be pregnant.

Do not breastfeed while using amivantamab, and for at least 3 months after your last dose.

How is amivantamab given?

Your doctor will perform tests to make sure amivantamab is the right treatment for you.

Amivantamab is given as an infusion into a vein by a healthcare provider. Your doctor will determine the right treatment schedule for you.

You may be given other medications to help prevent serious side effects or an allergic reaction. Keep using these medicines for as long as your doctor has prescribed.

You may need frequent vision exams.

This medicine may cause changes in the appearance of your skin and nails. Follow your doctor's instructions if you develop any symptoms.

Amivantamab dosing information

Usual Adult Dose for Non-Small Cell Lung Cancer:

Weeks 1 to 4:
-Less than 80 kg: 1050 mg IV once a week for 4 doses
-At least 80 kg: 1400 mg IV once a week for 4 doses

Week 5 onwards:
-Less than 80 kg: 1050 mg IV every 2 weeks
-At least 80 kg: 1400 mg IV every 2 weeks

Duration of therapy: Until disease progression or unacceptable toxicity.

Infusion Rates for 1050 mg Dose:
-Week 1 (split dose infusion):
---Day 1 (350 mg dose):
-----Initial rate: 50 mL/hour
-----Subsequent rate: 75 mL/hour
---Day 2 (700 mg dose):
-----Initial rate: 50 mL/hour
-----Subsequent rate: 75 mL/hour
-Week 2 (1050 mg dose): 85 mL/hour
-Subsequent weeks (1050 mg dose): 125 mL/hour

Infusion Rates for 1400 mg Dose:
-Week 1 (split dose infusion):
---Day 1 (350 mg dose):
-----Initial rate: 50 mL/hour
-----Subsequent rate: 75 mL/hour
---Day 2 (1050 mg dose):
-----Initial rate: 35 mL/hour
-----Subsequent rate: 50 mL/hour
-Week 2 (1400 mg dose): 65 mL/hour
-Week 3 (1400 mg dose): 85 mL/hour
-Subsequent weeks (1400 mg dose): 125 mL/hour

Comments:
-The dose should be based on baseline body weight; dose adjustments are not needed for subsequent body weight changes.
-The initial dose should be administered as a split infusion in Week 1, on Day 1 and Day 2.
-Before the initial infusion on Week 1 (Days 1 and 2), premedication should be administered to reduce the risk of infusion-related reactions.
---An antihistamine and antipyretic should be administered before all infusions.
---A glucocorticoid is required for Week 1 (Days 1 and 2) doses only and should be used as needed for subsequent infusions.
-The initial infusion rate may be increased to the subsequent infusion rate after 2 hours without an infusion-related reaction.

Use: For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by US FDA-approved test, whose disease has progressed on/after platinum-based chemotherapy

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your amivantamab injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid while receiving amivantamab?

Amivantamab can cause skin reactions. Avoid sunlight and tanning beds during treatment and for 2 months after your last dose. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.

If you have vision problems, avoid wearing contact lenses until your symptoms can be checked by an eye doctor (ophthalmologist).

What other drugs will affect amivantamab?

Other drugs may affect amivantamab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Popular FAQ

How does Rybrevant work?

Rybrevant is a targeted medicine that works at the epidermal growth factor receptor (EGFR) gene mutation and MET receptor found in certain types of non-small cell lung cancer (NSCLC). EGFR and MET are proteins that help cells to grow. Targeting these proteins helps to slow down or stop cancer growth. Continue reading

How is Rybrevant administered?

Rybrevant is given as an intravenous (IV) infusion into your vein. Your healthcare provider will administer this medication to you and determine your dose. It may be given alone, in combination with chemotherapy (carboplatin and pemetrexed), or with a kinase inhibitor called Lazcluze (lazertinib) for the treatment of EGFR mutated non-small cell lung cancer. Continue reading

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.